Pharmaceuticals Companies By Operating Cash Flow

Cash Flow From Operations
Cash Flow From OperationsEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
716.34 B
 0.20 
 1.16 
 0.23 
2NVO Novo Nordisk AS
120.97 B
(0.10)
 2.87 
(0.29)
3RDY Dr Reddys Laboratories
45.43 B
(0.17)
 1.54 
(0.27)
4JNJ Johnson Johnson
24.27 B
 0.21 
 1.14 
 0.24 
5MRK Merck Company
21.47 B
(0.08)
 1.82 
(0.15)
6NVS Novartis AG ADR
17.62 B
 0.22 
 1.34 
 0.30 
7BMY Bristol Myers Squibb
15.19 B
 0.07 
 1.60 
 0.11 
8PFE Pfizer Inc
12.74 B
(0.05)
 1.20 
(0.06)
9AZN AstraZeneca PLC ADR
11.86 B
 0.20 
 1.16 
 0.23 
10SNY Sanofi ADR
9.08 B
 0.16 
 1.37 
 0.23 
11LLY Eli Lilly and
8.82 B
 0.06 
 2.05 
 0.12 
12GSK GlaxoSmithKline PLC ADR
6.55 B
 0.16 
 1.73 
 0.27 
13ZTS Zoetis Inc
2.95 B
 0.03 
 1.65 
 0.05 
14RPRX Royalty Pharma Plc
2.77 B
 0.20 
 2.05 
 0.40 
15VTRS Viatris
2.3 B
(0.21)
 2.44 
(0.51)
16BHC Bausch Health Companies
1.6 B
(0.08)
 2.87 
(0.22)
17JAZZ Jazz Pharmaceuticals PLC
1.4 B
 0.03 
 1.80 
 0.06 
18TEVA Teva Pharma Industries
1.25 B
(0.20)
 2.85 
(0.57)
19OGN Organon Co
939 M
 0.03 
 2.77 
 0.07 
20ELAN Elanco Animal Health
541 M
(0.08)
 2.11 
(0.17)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings. Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.